Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Avelumab for People With Recurrent Respiratory Papillomatosis

ABSTRACT: Avelumab for People With Recurrent Respiratory Papillomatosis

PROVIDER: PRJNA713424 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Avelumab for People With Recurrent Respiratory Papillomatosis

Project description:Avelumab for People With Recurrent Respiratory Papillomatosis

| PRJNA713423 | ENA

Immune Dysregulation/Tumor-Associated Gene Changes in Recurrent Respiratory Papillomatosis: A Paired Microarray Analysis

2008-07-16 | GSE10935 | GEO

the role of HPV11 E7 in modulating sting-dependent interferon β response in recurrent respiratory papillomatosis

Project description:recurrent respiratory papillomatosis is a rare benign tumor caused mainly by the infection of the respiratory tract epithelial cells by the human papillamavirus type 6/11.the specific mechanisms underlying the inhibition of the host's innate immune response by HPV remian unclear.For this purpose,we employed single cell RNA sequencing to analyze the states of various immune cells in RRP samples post HPV infection.

2024-04-02 | GSE261589 | GEO

Transcription profiling of human immune dysregulation/tumor-associated gene changes in recurrent respiratory papillomatosis

Project description:The goal of this study was to determine the differential expression of specific genes within the papilloma tissues themselves and to characterize the array of host genes that might be important in the pathophysiology of recurrent respiratory papillomatosis. Experiment Overall Design: Total RNAs from papillomas (n=12) and adjacent tissues (n=12) were analyzed by Affymetrix microarray, and the matched sets of tissues compared by Genesifter paired t-test to identify differentially expressed genes in papilloma tissues while minimizing variations that are intrinsic to individual patients.

2008-10-20 | E-GEOD-10935 | biostudies-arrayexpress

A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis

Project description:A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis

| PRJNA996299 | ENA

A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis

Project description:A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis

| PRJNA996300 | ENA

the role of HPV11 E7 in modulating sting-dependent interferon β response in recurrent respiratory papillomatosis

Project description:the role of HPV11 E7 in modulating sting-dependent interferon β response in recurrent respiratory papillomatosis

| PRJNA1087889 | ENA

Recurrent respiratory papillomatosis: A 2020 perspective.

Project description:ObjectiveDespite recent advancement recurrent respiratory papillomatosis (RRP) remains a rare but challenging benign airway neoplasm. In recent years there has been significant shifts in incidence of this disease due to changes in vaccination and prevention for human papilloma virus (HPV) and its related pathology. This review will highlight the epidemiology, prevention and treatment of RRP.MethodsThe PubMed database was searched using relevant MeSH terms including "recurrent respiratory papillomatosis." The titles and abstracts were reviewed to assess relevance and unrelated articles were excluded. A full-text review for select articles was performed, the data and discussions were interpreted and synthesized to create a concise update on the management of RRP.ResultsWith the increasing utilization of the 9-valent and quadrivalent HPV vaccine in Australia, we have seen a significant decrease in the incidence of RRP. Preliminary data in the US shows a similar trend of decreased incidence after implementation of vaccination. Single dose Gardasil in developing countries has shown sustained immunization for at least 7 years. Preliminary clinical trials and retrospective studies have shown the HPV vaccine may have benefit as a treatment method in addition to prevention for HPV related diseases. Bevacizumab (Avastin), a VEGF monoclonal antibody, has shown promise as a systemic treatment for RRP. The Corona Virus Disease 2019 (COVID-19) pandemic has affected perioperative management of RRP.ConclusionRRP continues to decline in incidence since the implementation of HPV vaccination. Advancement in the medical management including Bevacizumab show promise as an additional option for the management of RRP.

| S-EPMC8035938 | biostudies-literature

Recurrent respiratory papillomatosis with lung involvement.

Project description:Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomavirus. Aggressive forms of RRP require repeated cytoreductive surgery to restore airway patency. Tracheal disease is even less common and lung parenchyma is involved in less than 1% of patients. We present reports of three cases of RRP with progressive lung disease in adult patients.

| S-EPMC6214881 | biostudies-literature

Current and future management of recurrent respiratory papillomatosis.

Project description:ObjectivesRecurrent respiratory papillomatosis (RRP) is a chronic disease of the respiratory tract that occurs in both children and adults. It is caused by the human papillomavirus (HPV), in particular low-risk HPV6 and HPV11, and aggressiveness varies among patients. RRP remains a chronic disease that is difficult to manage. This review provides perspectives on current and future management of RRP.ResultsThe current standard of care is surgical excision, with adjuvant therapies as needed. Surgical management of RRP has evolved with the introduction of microdebriders and photoangiolytic lasers; the latter can now be used in the office setting. Numerous adjuvant pharmacologic therapies have been utilized with some success. Also, exciting preliminary data show that HPV vaccines may prolong the time to recurrence in the RRP population. There is also optimism that wide-spread HPV vaccination could reduce RRP incidence indirectly by preventing vertical HPV transmission to newborns.ConclusionTo date, the biology of RRP is not well understood, although it has been noted to become more aggressive in the setting of immune suppression. Additional research is needed to better understand immune system dysfunction in RRP such that immunomodulatory approaches may be developed for RRP management.Level of evidence4.

| S-EPMC5824106 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data